Challenges Arise as Public Health and Scientific Communication Enters Uncharted Territory
It is difficult to dispute that these are troubling times for government officials and public health agencies.
Related Articles
ASCO Congratulates 2024 Special Awards Recipients
ASCO and Conquer Cancer will honor individuals who have significantly impacted global cancer care across various domains at the 2024 ASCO Annual Meeting.
FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain
Experts discuss the FDA’s call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.
Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates
Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
European Medicines Agency Grants Orphan Drug Designation to Annamycin in AML
The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.
FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection
The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.
Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer
Anne Favret, MD discusses the FDA approval of capivasertib in combination with fulvestrant for HR-positive, HER2-negative breast cancer.